Atossa Therapeutics CEO Steven Quay joins ARDD 2026 panel on clinical trials, regulatory pathways for aging diseases

ATOS•2026-09-24

Atossa Therapeutics CEO Steven Quay will speak at ARDD 2026 at Harvard University in Boston on Oct. 1, 2026, on a panel about clinical trials and regulatory pathways for diseases of aging.

1. Conference panel

Quay is scheduled to speak from 11:20 a.m. to 12:00 p.m. ET at the ARDD 2026 panel on clinical trials and regulatory pathways for diseases of aging.

Atossa Therapeutics CEO Steven Quay joins ARDD 2026 panel on clinical trials, regulatory pathways for aging diseases

1. Conference panel

Related News

Digital Turbine Chief Business Officer Michael Akkerman resigns effective Oct. 30

Trump rolled back regulations for oil company campaign donors, Democrats say

US Q2 current account data

Oppenheimer raises Okta target price to $227 from $190

Netlist says US ITC opens Micron import probe over four patents